Frequency of CYP2C9 genotypes among Omani patients receiving warfarin and its correlation with warfarin dose

Community Genet. 2007;10(1):32-7. doi: 10.1159/000096279.

Abstract

Objectives: This study was conducted to determine the frequency of CYP2C9 alleles in Omani patients receiving warfarin and to correlate genotyping data with warfarin dosage. The Omani population has Asian and African ethnicities.

Methods: CYP2C9 genotypes were determined by the polymerase chain reaction restriction fragment length polymorphism method. Non-parametric Kruskal-Wallis test was used to compare groups of continuous data for significance differences.

Results: Genotyping data showed that 12.7 and 5.8% of the samples were heterozygous for the CYP2C9*2 and CYP2C9*3 alleles, respectively. The CYP2C9*2 allele frequency was 0.074 in our population. It was 0.029 for CYP2C9*3.

Conclusion: This is the first report on the presence of CYP2C9*2 allele homozygocity in any Asian or African population.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Alleles
  • Anticoagulants / administration & dosage*
  • Anticoagulants / metabolism
  • Aryl Hydrocarbon Hydroxylases / genetics*
  • Cytochrome P-450 CYP2C9
  • Female
  • Gene Frequency*
  • Genotype*
  • Humans
  • Male
  • Middle Aged
  • Oman
  • Pharmacogenetics
  • Polymerase Chain Reaction
  • Polymorphism, Restriction Fragment Length
  • Warfarin / administration & dosage*
  • Warfarin / metabolism

Substances

  • Anticoagulants
  • Warfarin
  • CYP2C9 protein, human
  • Cytochrome P-450 CYP2C9
  • Aryl Hydrocarbon Hydroxylases